First Wave BioPharma, Inc.

First Wave BioPharma, Inc.verified

FWBI

Price:

$2.96

Market Cap:

$5.99M

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties; and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ...[Read more]

Industry

Biotechnology

IPO Date

2016-10-11

Stock Exchange

NASDAQ

Ticker

FWBI

The Enterprise Value as of November 2024 (TTM) for First Wave BioPharma, Inc. (FWBI) is 9.55M

According to First Wave BioPharma, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 9.55M. This represents a change of 129.67% compared to the average of 4.16M of the last 4 quarters.

First Wave BioPharma, Inc. (FWBI) Historical Enterprise Value (quarterly & annually)

How has FWBI Enterprise Value performed in the past?

The mean historical Enterprise Value of First Wave BioPharma, Inc. over the last ten years is 278.18M. The current 9.55M Enterprise Value has changed 243.16% with respect to the historical average. Over the past ten years (40 quarters), FWBI's Enterprise Value was at its highest in in the March 2021 quarter at 1.47B. The Enterprise Value was at its lowest in in the September 2023 quarter at -866895.00.

Quarterly (TTM)
Annual

Average

278.18M

Median

23.45M

Minimum

-1472289.60

Maximum

965.20M

First Wave BioPharma, Inc. (FWBI) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of First Wave BioPharma, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = Infinity%

Maximum Annual Enterprise Value = 965.20M

Minimum Annual Increase = -137.51%

Minimum Annual Enterprise Value = -1472289.60

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2023-1472289.60-137.51%
20223.93M-30.89%
20215.68M-74.36%
202022.15M-10.51%
201924.75M-93.36%
2018372.77M-51.77%
2017772.93M25.69%
2016614.93M-36.29%
2015965.20M100.71%
2014957.45KInfinity%

First Wave BioPharma, Inc. (FWBI) Average Enterprise Value

How has FWBI Enterprise Value performed in the past?

The current Enterprise Value of First Wave BioPharma, Inc. (FWBI) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

2.71M

5-year avg

11.01M

10-year avg

278.18M

First Wave BioPharma, Inc. (FWBI) Enterprise Value vs. Peers

How is FWBI’s Enterprise Value compared to its peers?

First Wave BioPharma, Inc.’s Enterprise Value is greater than Quoin Pharmaceuticals, Ltd. (-162664.00), greater than Blue Water Vaccines, Inc. (8.67M), greater than PaxMedica, Inc. Common Stock (757.99K), greater than Revelation Biosciences, Inc. (-3300245.00), greater than Hillstream BioPharma, Inc. (1.48M), greater than Dermata Therapeutics, Inc. (-3823196.00), greater than Panbela Therapeutics, Inc. (4.75M), greater than ContraFect Corporation (-2860000.00), greater than SeaStar Medical Holding Corporation (7.07M), greater than Virios Therapeutics, Inc. (-2813681.00), greater than ZyVersa Therapeutics, Inc. (2.53M), greater than Sonnet BioTherapeutics Holdings, Inc. (-907921.00), greater than Cardio Diagnostics Holdings, Inc. (9.47M), less than Sigilon Therapeutics, Inc. (42.21M), less than X4 Pharmaceuticals, Inc. (38.44M), greater than Zura Bio Limited (-9969663.00), greater than Apexigen, Inc. (-5121682.00), greater than Phio Pharmaceuticals Corp. (-2783607.00), greater than eFFECTOR Therapeutics, Inc. (4.74M), less than Immix Biopharma, Inc. (30.53M),

Build a custom stock screener for First Wave BioPharma, Inc. (FWBI) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like First Wave BioPharma, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

First Wave BioPharma, Inc. (FWBI) and other stocks custom spreadsheet templates

The easiest way to analyze a company like First Wave BioPharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is First Wave BioPharma, Inc.'s Enterprise Value?

What is the highest Enterprise Value for First Wave BioPharma, Inc. (FWBI)?

What is the 3-year average Enterprise Value for First Wave BioPharma, Inc. (FWBI)?

What is the 5-year average Enterprise Value for First Wave BioPharma, Inc. (FWBI)?

How does the current Enterprise Value for First Wave BioPharma, Inc. (FWBI) compare to its historical average?